Company Profile
Milo Biotechnology is a Cleveland, OH based company developing therapies to increase muscle strength and prevent muscle atrophy. The company’s lead program is a skeletal muscle specific transgene of the protein follistatin. The follistatin 344 transgene is delivered via an adeno-associated virus to achieve long lasting and potent expression in muscle. Milo is currently engaged in three clinical studies for rare muscular dystrophies. Milo Biotechnology’s therapy is based on adeno-associated virus (AAV) delivery of follistatin. AAVs are small, non-pathogenic carriers that can be tailored to deliver sustained administration of follistatin via a single dose.
